Literature DB >> 8495082

Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients.

U Nieminen1, H Peltola, M T Syrjälä, A Mäkipernaa, R Kekomäki.   

Abstract

An acute thrombocytopenic purpura developed shortly after measles-mumps-rubella vaccination in 23 of approximately 700,000 children immunized over a period of seven years. The mean interval from inoculation to the onset of purpura was 19 days. Bone marrow aspirates obtained from 13 patients showed increased or normal amounts of megakaryocytes. Platelet survival time was markedly shortened in the two patients studied. Fifteen patients recovered (the platelet count exceeded 100 x 10(9)/l) in one month, five in two months and two in six months. Increase in platelet-associated immunoglobulin was detected in 10 of 15 patients. Circulating antiplatelet autoantibodies (AAb) against glycoprotein IIb/IIIa were detected in 5 of 15 patients. The findings are compatible with an autoimmune mechanism triggered by immune response to measles-mumps-rubella vaccination. As evaluated by the clinical course and the presence of AAb, post-vaccination thrombocytopenic purpura appears to be indistinguishable from childhood acute idiopathic thrombocytopenic purpura.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8495082     DOI: 10.1111/j.1651-2227.1993.tb12657.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  13 in total

1.  The reporting sensitivities of two passive surveillance systems for vaccine adverse events.

Authors:  S Rosenthal; R Chen
Journal:  Am J Public Health       Date:  1995-12       Impact factor: 9.308

Review 2.  Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases.

Authors:  Carlo Perricone; Fulvia Ceccarelli; Gideon Nesher; Elisabetta Borella; Qasim Odeh; Fabrizio Conti; Yehuda Shoenfeld; Guido Valesini
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 3.  Vaccine administration and the development of immune thrombocytopenic purpura in children.

Authors:  Valerio Cecinati; Nicola Principi; Letizia Brescia; Paola Giordano; Susanna Esposito
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

4.  Idiopathic thrombocytopenic purpura and MMR vaccine.

Authors:  E Miller; P Waight; C P Farrington; N Andrews; J Stowe; B Taylor
Journal:  Arch Dis Child       Date:  2001-03       Impact factor: 3.791

5.  Atorvastatin-related thrombocytopenic purpura.

Authors:  Deepa Narayanan; Eric S Kilpatrick
Journal:  BMJ Case Rep       Date:  2010-05-19

Review 6.  Cancer chemotherapy: identifying novel anticancer drugs.

Authors:  J Carmichael
Journal:  BMJ       Date:  1994-05-14

Review 7.  Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?

Authors:  Maria Vadalà; Dimitri Poddighe; Carmen Laurino; Beniamino Palmieri
Journal:  EPMA J       Date:  2017-07-20       Impact factor: 6.543

Review 8.  Brief report: immune factors in autism: a critical review.

Authors:  Ilan Krause; Xiao-Song He; M Eric Gershwin; Yehuda Shoenfeld
Journal:  J Autism Dev Disord       Date:  2002-08

Review 9.  Safety of routine childhood vaccinations. An epidemiological review.

Authors:  R T Chen; G Mootrey; F DeStefano
Journal:  Paediatr Drugs       Date:  2000 Jul-Aug       Impact factor: 3.930

Review 10.  Autoimmune reaction after anti-tetanus vaccination-description of four cases and review of the literature.

Authors:  N Ruhrman-Shahar; J Torres-Ruiz; P Rotman-Pikielny; Y Levy
Journal:  Immunol Res       Date:  2017-02       Impact factor: 4.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.